| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 263.71 | 22.0% | 45.4% |
| Total Income | 263.71 | 22.0% | 45.4% |
| Expenditure | 236.79 | 12.3% | 18.8% |
| PBT | -0.61 | 4.7% | 99.2% |
| Net Profit | -0.64 | 25.5% | 99.1% |
| OPM | 10.21% | 7.77pp | 20.13pp |
| NPM | -0.24% | 0.01pp | 39.33pp |
| EPS | 0.00 | 100.0% |
Caris Life Sciences Reports Q2 2026 Financial Results and Increases Guidance
06 Aug 2026 · 6 Aug, 1:52 am
Summary
Caris Life Sciences reported strong financial results for the second quarter of 2026, with total revenue reaching $263.7 million, a 45% increase year-over-year, driven by a 55% growth in molecular profiling services. The company also saw a significant improvement in gross margin to 68% and narrowed its net loss to $0.6 million. Management raised the full-year 2026 revenue guidance to $1.03-$1.04 billion, reflecting confidence in continued growth.
Key Highlights
- 1
Caris Life Sciences reported total revenue of $263.7 million for the second quarter of 2026, an increase of 45% over the corresponding prior year period.
- 2
The company completed approximately 59,200 clinical cases in Q2 2026, an increase of approximately 18% over the corresponding prior year period.
- 3
Gross margin improved to 68% in Q2 2026, an approximate 500 bps improvement over the corresponding prior year period.
- 4
Net loss for the second quarter of 2026 was $0.6 million, a significant improvement from a net loss of $71.8 million in the prior year period.
- 5
Adjusted EBITDA was positive $55.7 million for Q2 2026.
- 6
Caris Life Sciences raised its full year 2026 revenue guidance to a range of $1.03 billion to $1.04 billion, representing growth of 27% to 28% compared to full year 2025.
Management Comments
David Dean Halbert
This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine. Our comprehensive approach gives every case real molecular depth, across more than 1.13 million patients with AI trained on it, that depth is what powers Caris Detect. And Detect doesn't stop at finding cancer early, through what we call the Mutational Cleanse, we plan to turn an early signal into personalized immune targets, moving from early detection to early interception. It all comes back to one thing: making precision medicine a reality for every patient.
Informational and educational content only. Not investment advice.